ABSTRACT
INTRODUCTION
Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system (CNS). MS is characterized by perivenular infiltration of lymphocytes and macrophages in the parenchyma of the brain, brain stem, optic nerves, and spinal cord
(1). MS is a dynamic disease, with almost constant lesion formation and a progressive clinical course leading to physical disability. The disease can present in different forms, such as primary progressive, relapsing remitting, and secondary progressie phenotypes.
(2).
Dysregulation of the blood-brain barrier (BBB) and transendothelial migration of activated leukocytes are among the earliest cerebrovascular abnormalities seen in multiple sclerosis (MS) and parallel the release of inflammatory cytokines/ chemokines.
Mechanisms for breakdown of the BBB in MS are incompletely understood, but appear to involve direct effects of these cytokines/chemokines on endothelial regulation of BBB components, as well as indirect cytokine/chemokinedependent leukocyte mediated injury
(3).
The measurement of brain atrophy by magnetic resonance imaging (MRI) was reported to be sufficiently precise and accurate. It also represents one of most promising in vivo measures of neuroaxonal degeneration in MS, and it should be used extensively in the future to assess and monitor pathological evolution and treatment efficacy in this disease (4, 5) . However, Miller et al.
(6) reported that MRI scanning lacks precision in estimating the overall extent of BBB disruption and that correlation of the MRI scan with clinical findings and disability has been disappointing.
Developing new MS biomarkers that are sensitive and specific for BBB disruption could improve the monitoring of disease activity and response to MS therapies, and advance our understanding of dynamic MS processes participating in BBB disruption Interleukin-12 (IL-12) is a proinflammatory cytokine produced primarily by blood mononuclear cells, including dendritic cells in response to antigens and mitogens (9) . It is a potent inducer of interferon-gamma (IFN-γ), and other Th1 cytokines that may play an important role in MS pathogenesis (10) . Interleukin-17 (IL-17) is a cytokine produced in humans almost exclusively by activated memory T cells, which can induce the production of proinflammatory cytokines and chemokines from parenchymal cells and macrophages The present study aimed to estimate the serum levels of IL-12 and IL-17 (cytokines) and sVCAM (an adhesion molecule) in different MS subtypes and to assess their relationship to disease activity, disability and MRI findings of cerebral atrophy. 
SUBJECTS & METHODS

Fifty
C) Radiological assessment
All patients selected were previously diagnosed as MS clinically and confirmed by Magnetic resonance imaging (MRI). All patients had either brain or spinal cord lesions.
Brain MRI was done within one week of blood sampling for all patients. MRI was performed using 1-tesla intera (Philips) and 0. Blood samples were collected by venipuncture in empty centrifuge tubes. Sera were separated and divided into aliquots and stored at -80°C till used. Haemolysed samples were discarded.
In relapsing remitting patients who were admitted to the hospital during relapse, and in secondary progressive patients, blood samples were collected on admission before starting pulse therapy (in the form of methylprednisolone, (1g) by intravenous infusion daily for 5 -7 days during acute exacerbations, followed by oral prednisolone in a tapering schedule). 
RESULTS
All patients and controls were age matched. No statistical significant difference was detected between the different studied groups concerning age (p > 0.05). The mean value of EDSS score was significantly higher in the secondary progressive (SP) patients (group III) compared to patients with RRMS in remission (group I, P=0.0001) and in relapse (group I, P=0.0001). No significant difference was detected between group I (RRMS in remission) and group II (RRMS in relapse) (P>0.05) [ Table  ( 
The mean of total number of relapses was significantly higher in both the RRMS in relapse (group II) and SPMS (group III) compared to RRMS in remission (group I) (P=0.004 and 0.01, respectively). However, no significant difference was detected between RRMS in relapse (group II) and SPMS (group III, P>0.05) [ Table ( 1)].
The mean values of the lesion load detected by MRI was significantly higher in the RRMS in relapse (group II) compared to each of RRMS in remission (group I) and SPMS (group III) (P=0.0001 and P=0.01, respectively). SPMS (group III) also showed significantly higher levels compared to RRMS in remission (group I, P=0.01) [ Table  ( 1)]. In Table ( 2), the mean levels of serum IL-12, IL-17 and sVCAM in all patients' groups were significantly higher compared to the control group. The mean levels of these parameters were significantly higher in the SPMS patients (group III) compared to each of group I (RRMS in remission) and group II (RRMS in relapse) (P=0.0001 for each). A significant difference was detected between mean levels of group II (RRMS in relapse) versus group I (RRMS in remission) (P<0.05) [ Table ( (Fig.4 ).
-MRI detected signs of cerebral atrophy in 17 patients; 4 from RRMS in remission group, 3 from RRMS in relapse group and 10 patients from SPMS group. The present study aimed to estimate the serum levels of IL-12 and IL-17 (cytokines) and sVCAM (an adhesion molecule) in different MS subtypes and to assess their relationship to disease activity, disability and MRI findings of cerebral atrophy.
In the present study the mean serum levels of each of studied biomarkers IL-12, IL-17 and sVCAM were elevated in all MS groups compared to the control group. Significantly higher levels were detected in SPMS versus RRMS groups (whether in relapse or RRMS in remission). The levels of the above biomarkers were significantly higher in RRMS in relapse versus RRMS in remission. The three biomarkers of activity or inflammation were significantly correlated to each other. Inflammation is thought to occur early during the relapsing-remitting phase of MS (RRMS), whereas in the later phases of MS such as secondary progressive MS (SPMS INF-β, which has been used to treat patients with multiple sclerosis, was thought to cause a shift from a Th1-mediated to a Th2-mediated response. INF-β has been shown to significantly increase the expression of the anti-inflammatory cytokine IL-10. An important property of IL-10 is its capacity to inhibit Th1 cells. This is mediated by several mechanisms including inhibition of IL-12 production and blocking of INF-γ synthesis by differentiated Th1
(44, 45) . It is interesting that the progressive stage of MS is characterized by a loss of the ability of IL-10 to suppress INF-γ and IL-12, as higher levels of IL-12 are detected (2) . In addition, Martin-Saavedra et al.
(46) suggested that the inhibition of nuclear DNA binding activity levels of NF-kappaB, the increase of IL-4 expression and its signaling transduction, and the decrease of IL-17 may cooperate to some of the anti-inflammatory effects of INF-β on experimental-induced encephalomyelitis (EAE).
In an un-stimulated state, leukocytes do not readily adhere to the vascular endothelium. However, inflammatory signals induce the expression of proteins on the endothelial cell surface that promote the adhesion and extravasations of activated immune cells from the circulation into the underlying tissues.
Key among these molecules are Pand E-selectin, intercellular adhesion molecule-1 (ICAM-1) and VCAM-1 on the endothelial cells, and their respective counter receptors, Pselectin glycoprotein ligand-1 (PSGL-1), leukocyte function-associated antigen-1 (LFA-1) and very late antigen-4 (VLA-4), on the leukocytes (47) . Through interaction with its ligand, VCAM-1, the integrin, VLA-4, has been implicated in Th-1 also reported higher levels of sVCAM in SPMS than in RRMS. They added that up regulated sVCAM in blood and CSF indicate sustained potential for inflammation in the CNS throughout the clinical spectrum of MS. They suggested that some functional alteration of hematoencephalic barrier (HEB) endothelium, manifest in constant pathologic expression of sVCAM-1 molecule, is one of the pathochemical mechanisms promoting progression of MS process. This may explain the significantly higher levels of sVCAM in SPMS than in RRMS in the present study. Baraczka et al. (53) reported that BBB damage can be assumed through higher sVCAM-1 levels. They added that clinical forms of MS differ from each other in respect to concentrations of adhesion molecules.
Giovannoni et al.
(54) found no correlation between mean levels of inflammatory markers as sVCAM-1, sICAM-1, and/or C-reactive protein (CRP)) and disease progression or changes in any of the MRI measures, disease course or relapse-rate. The difference in the MS subtypes may be attributed to the protective role of NO level. They reported that the mean levels of NO were significantly higher in patients with RRMS than in patients with SP disease. In addition raised levels of serum nitric oxide metabolites are associated with a lower number of clinical relapses and a non-progressive disease course (54) . EDSS score showed significantly higher levels in SPMS compared to both RRMS whether in relapse or remission. However no significant difference was detected between RR in relapse and in remission. This could be attributed to the severity and progression of the course of the disease in the former subtype of MS compared with RR subtypes leading to a higher degree of disability.
EDSS correlated significantly with IL-12 and correlated weakly with each of IL-17 and sVCAM. This is in agreement with the generalized view of these cytokines and adhesion molecules as being reliable markers of inflammation or activity and not of disability. In accordance with the present results, Makhlouf et al. (55) reported that increased IL-12 expression correlated with disability, as measured by EDSS, and also with disease activity, measured by the presence of gadolinium-enhancing magnetic resonance imaging (MRI) lesions. Rolland et al. (27) reported that the overproduction of IL-12p40 in MS correlated with disease severity (EDSS) in most patients. On the contrary, Bartosik-Psujek et al. (26) found no relation between the severity of disability and the levels of IL-12, thus excluding its possible role as a prognostic factor allowing to anticipate the consequences of the relapse.
Brain atrophy is a relevant surrogate marker of the disease process in MS because it represents the net effect of various pathological processes leading to brain tissue loss. There are various approaches to quantifying central nervous system atrophy in MS. Magnetic resonance imaging (MRI) has been widely used to diagnose and monitor MS. Neurodegeneration is increasingly being recognized as an important factor in the pathogenesis of MS, and MRI measures of brain atrophy have been suggested as surrogate markers of neuroaxonal loss and disease progression. This pathology may be more relevant to the progression of disability than focal inflammation (56) . Patients with MRI signs of cerebral atrophy in the present study showed significant higher levels of EDSS score and serum IL-12, IL-17 and sVCAM levels versus patients without cerebral atrophy, suggesting that the inflammation does not decrease in the stage of brain atrophy and/or brain atrophy may occur early in the course of MS. However no significant difference was found in total number of relapses or lesion load between the two groups. A significant correlation was found between the presence of cerebral atrophy and the EDSS score, denoting most probably that the MS-associated disability accentuates with loss of brain tissue. However, no significant correlations could be detected between cerebral atrophy and the biomarkers; IL-12, IL-17 and sVCAM.
It is to be noted, in the present, study that ten out of the 17 patients that showed MRI signs of cerebral atrophy, were from SPMS group in which the three biomarkers showed highest levels. These results denote that cerebral atrophy and disability occur in the advanced MS subtypes.
Rudick et al. (57) reported that EDSS pointing from baseline and persisting at least 6 months, was associated with significantly greater brain atrophy progression. Bakshi et al. reported that disease progression required a sustained change in the EDSS. They found no correlation between mean levels of inflammatory markers over the study period and disease progression or changes in any of the MRI measures. 
Conclusion
